Q1 Earnings Estimate for Neurogene Issued By Lifesci Capital

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at Lifesci Capital lowered their Q1 2026 EPS estimates for Neurogene in a research note issued on Tuesday, March 24th. Lifesci Capital analyst P. Dolezal now forecasts that the company will earn ($1.26) per share for the quarter, down from their previous forecast of ($1.19). Lifesci Capital has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Lifesci Capital also issued estimates for Neurogene’s Q2 2026 earnings at ($1.28) EPS, Q3 2026 earnings at ($1.04) EPS, Q4 2026 earnings at ($1.06) EPS and FY2026 earnings at ($4.59) EPS.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.08.

Several other research firms have also weighed in on NGNE. Wall Street Zen lowered shares of Neurogene from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group started coverage on Neurogene in a research report on Friday, February 27th. They issued a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Neurogene Stock Performance

Shares of NASDAQ:NGNE opened at $21.41 on Thursday. The company has a market capitalization of $333.35 million, a PE ratio of -5.05 and a beta of 1.53. Neurogene has a 52 week low of $6.88 and a 52 week high of $37.27. The company’s fifty day moving average is $19.46 and its 200-day moving average is $21.65.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Neurogene by 24.7% in the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after buying an additional 1,000 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Neurogene by 3.4% in the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock valued at $531,000 after buying an additional 1,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after buying an additional 1,059 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in shares of Neurogene during the fourth quarter worth $66,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Insiders Place Their Bets

In related news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares in the company, valued at $634,642.57. This trade represents a 18.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $20.81, for a total value of $84,176.45. Following the sale, the chief financial officer directly owned 105,798 shares of the company’s stock, valued at $2,201,656.38. This represents a 3.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 11.64% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.